David Shaw’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.9M | Sell |
56,515
-21,913
| -28% | -$5.16M | 0.01% | 1361 |
|
|
2026
Q1 | $15.7M | Buy |
78,428
+41,877
| +115% | +$8.29M | 0.01% | 1306 |
|
|
2025
Q4 | $6.91M | Buy |
36,551
+19,037
| +109% | +$3.66M | ﹤0.01% | 2059 |
|
|
2025
Q3 | $3.1M | Buy |
17,514
+10,363
| +145% | +$1.54M | ﹤0.01% | 2616 |
|
|
2025
Q2 | $813K | Buy |
+7,151
| New | +$764K | ﹤0.01% | 3373 |
|
|
2024
Q3 | – | Sell |
-25,743
| Closed | -$2.17M | – | 4732 |
|
|
2024
Q2 | $2.17M | Sell |
25,743
-36,849
| -59% | -$2.93M | ﹤0.01% | 2588 |
|
|
2024
Q1 | $4.58M | Sell |
62,592
-25,317
| -29% | -$1.87M | ﹤0.01% | 1957 |
|
|
2023
Q4 | $6.28M | Sell |
87,909
-17,812
| -17% | -$1.05M | 0.01% | 1728 |
|
|
2023
Q3 | $6.33M | Buy |
105,721
+54,347
| +106% | +$3.58M | 0.01% | 1617 |
|
|
2023
Q2 | $3.7M | Buy |
51,374
+2,037
| +4% | +$153K | ﹤0.01% | 2107 |
|
|
2023
Q1 | $3.63M | Sell |
49,337
-1,964
| -4% | -$140K | ﹤0.01% | 2217 |
|
|
2022
Q4 | $3.43M | Buy |
+51,301
| New | +$3.34M | ﹤0.01% | 2452 |
|
|
2021
Q2 | – | Sell |
-10,222
| Closed | -$850K | – | 4892 |
|
|
2021
Q1 | $972K | Sell |
10,222
-43,142
| -81% | -$4.08M | ﹤0.01% | 3136 |
|
|
2020
Q4 | $3.31M | Sell |
53,364
-70,998
| -57% | -$4.05M | ﹤0.01% | 2194 |
|
|
2020
Q3 | $7.39M | Sell |
124,362
-148,826
| -54% | -$10.2M | 0.01% | 1431 |
|
|
2020
Q2 | $19.1M | Buy |
273,188
+7,401
| +3% | +$469K | 0.02% | 807 |
|
|
2020
Q1 | $12.1M | Buy |
265,787
+143,045
| +117% | +$8.11M | 0.02% | 890 |
|
|
2019
Q4 | $7.99M | Buy |
122,742
+103,785
| +547% | +$6.94M | 0.01% | 1371 |
|
|
2019
Q3 | $1.18M | Buy |
18,957
+12,378
| +188% | +$777K | ﹤0.01% | 2737 |
|
|
2019
Q2 | $468K | Sell |
6,579
-19,398
| -75% | -$1.43M | ﹤0.01% | 3107 |
|
|
2019
Q1 | $2.04M | Sell |
25,977
-244,875
| -90% | -$18.6M | ﹤0.01% | 2150 |
|
|
2018
Q4 | $22.9M | Buy |
270,852
+221,388
| +448% | +$23.6M | 0.03% | 651 |
|
|
2018
Q3 | $8.47M | Sell |
49,464
-79,440
| -62% | -$12M | 0.01% | 1217 |
|
|
2018
Q2 | $16.7M | Buy |
128,904
+39,929
| +45% | +$4.46M | 0.02% | 819 |
|
|
2018
Q1 | $9.17M | Sell |
88,975
-18,144
| -17% | -$1.79M | 0.01% | 1047 |
|
|
2017
Q4 | $9.15M | Buy |
107,119
+48,077
| +81% | +$4.17M | 0.01% | 1081 |
|
|
2017
Q3 | $5.01M | Buy |
+59,042
| New | +$4.68M | 0.01% | 1372 |
|
|
2017
Q1 | – | Sell |
-4,134
| Closed | -$272K | – | 3458 |
|
|
2016
Q4 | $262K | Buy |
+4,134
| New | +$261K | ﹤0.01% | 3165 |
|
|
2016
Q3 | – | Sell |
-51,102
| Closed | -$3.8M | – | 3457 |
|
|
2016
Q2 | $3.8M | Buy |
51,102
+42,754
| +512% | +$3.17M | 0.01% | 1460 |
|
|
2016
Q1 | $558K | Sell |
8,348
-57,460
| -87% | -$3.49M | ﹤0.01% | 2727 |
|
|
2015
Q4 | $4.45M | Buy |
+65,808
| New | +$4.06M | 0.01% | 1493 |
|
|
2015
Q3 | – | Sell |
-60,898
| Closed | -$3.7M | – | 3817 |
|
|
2015
Q2 | $3.83M | Buy |
60,898
+28,816
| +90% | +$1.57M | 0.01% | 1674 |
|
|
2015
Q1 | $1.54M | Buy |
+32,082
| New | +$1.23M | ﹤0.01% | 2212 |
|
|
2014
Q3 | – | Sell |
-9,185
| Closed | -$357K | – | 4258 |
|
|
2014
Q2 | $357K | Buy |
+9,185
| New | +$373K | ﹤0.01% | 3750 |
|
|
2014
Q1 | – | Sell |
-23,101
| Closed | -$963K | – | 4459 |
|
|
2013
Q4 | $758K | Buy |
23,101
+271
| +1% | +$8.83K | ﹤0.01% | 3399 |
|
|
2013
Q3 | $616K | Buy |
22,830
+9,852
| +76% | +$277K | ﹤0.01% | 3417 |
|
|
2013
Q2 | $303K | Buy |
+12,978
| New | +$233K | ﹤0.01% | 3565 |
|
Other funds holding LGND
JT
CAM
David Shaw's LGND Position: Q2 2026 in Review
David Shaw reduced its Ligand Pharmaceuticals (LGND) stake by 28% in Q2 2026, selling an estimated $5.16M and leaving 56,515 shares worth $17.9M. The position accounts for 0.01% of the portfolio, ranked #1361.
David Shaw first reported a position in LGND in Q2 2013 and has held it in 37 quarters since. The position peaked at $22.9M in Q4 2018. 413 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- David Shaw held 56,515 shares of Ligand Pharmaceuticals worth $17.9M as of Q2 2026.
- David Shaw sold 21,913 Ligand Pharmaceuticals shares in Q2 2026, an estimated $5.16M.
- Ligand Pharmaceuticals made up 0.01% of David Shaw's portfolio in Q2 2026, its #1361 holding.
- David Shaw first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
- David Shaw's Ligand Pharmaceuticals position peaked at $22.9M in Q4 2018.
- 413 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.